Holen Sie sich die Stockscreener-App
11.23
3.77%
-0.44
Handel nachbörslich:
11.23
Schlusskurs vom Vortag:
$11.67
Offen:
$11.63
24-Stunden-Volumen:
1.02M
Relative Volume:
1.24
Marktkapitalisierung:
$614.05M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-8.7054
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
-6.96%
1M Leistung:
+20.36%
6M Leistung:
+39.68%
1J Leistung:
+80.26%
1-Tages-Spanne:
$11.10
$11.71
1-Wochen-Bereich:
$11.10
$12.21
52-Wochen-Spanne:
$5.45
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Vergleichen Sie ZVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
11.23 | 638.11M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
What drives Zevra Therapeutics Inc. stock priceOutstanding stock performance - PrintWeekIndia
What analysts say about Zevra Therapeutics Inc. stockSuperior stock growth - PrintWeekIndia
Zevra Therapeutics Inc. Stock Analysis and ForecastExplosive wealth accumulation - jammulinksnews.com
Is Zevra Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire
Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases - TipRanks
ZVRA Showcases Key Findings on MIPLYFFA and OLPRUVA at Genetics - GuruFocus
Zevra Therapeutics Highlights Research on MIPLYFFA® and OLPRUVA® at 42nd Annual SERGG Meeting - Nasdaq
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
William Blair Issues Optimistic Forecast for ZVRA Earnings - Defense World
Zevra Therapeutics' MIPLYFFA: A Paradigm Shift in Rare Disease Treatment - AInvest
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice - Yahoo Finance
5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C - Nasdaq
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism - The Manila Times
Breakthrough: New Clinical Data Shows MIPLYFFA Halts Rare Brain Disease Progression for 5 Years - Stock Titan
Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - The Globe and Mail
ZVRA Publishes Positive Long-term Results for Arimoclomol in NPC Treatment | ZVRA Stock News - GuruFocus
Why Zevra Therapeutics Inc. stock attracts strong analyst attentionEarly Buy Suggestion - newser.com
What makes Zevra Therapeutics Inc. stock price move sharplyHigh Yield Stock Selection - Newser
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know - Yahoo Finance
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) - Yahoo Finance
How Zevra Therapeutics Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings - Defense World
Cantor Fitzgerald Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen - Defense World
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) - GlobeNewswire
Zevra(ZVRA) Soars 4.41% on Phase 2 Trial, Strategic Collaboration - AInvest
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):